Do you prefer using an anthracycline or non-anthracycline adjuvant regimen in BRCA+ premenopausal patients with localized HR+ breast cancer?
Assuming chemotherapy is indicated because of the Oncotype score.
Answer from: Medical Oncologist at Academic Institution
My choice of chemotherapy for localized BRCA+ breast cancer is guided by the patient's risk factors such as tumor grade, tumor size, presence or absence of lymphovascular invasion, number of lymph nodes involved, Oncotype dx result, and the patient's age. For small, node negative, HR+, HER2- breast ...
Sign in or Register to read more